<?xml version='1.0' encoding='utf-8'?>
<document id="30418178"><sentence text="A Phase Ib Study of the FGFR/VEGFR Inhibitor Dovitinib With Gemcitabine and Capecitabine in Advanced Solid Tumor and Pancreatic Cancer Patients."><entity charOffset="60-71" id="DDI-PubMed.30418178.s1.e0" text="Gemcitabine" /><entity charOffset="76-88" id="DDI-PubMed.30418178.s1.e1" text="Capecitabine" /><pair ddi="false" e1="DDI-PubMed.30418178.s1.e0" e2="DDI-PubMed.30418178.s1.e0" /><pair ddi="false" e1="DDI-PubMed.30418178.s1.e0" e2="DDI-PubMed.30418178.s1.e1" /></sentence><sentence text="Preclinical studies demonstrated antitumor activity of dovitinib in pancreatic cancer models"><entity charOffset="55-64" id="DDI-PubMed.30418178.s2.e0" text="dovitinib" /></sentence><sentence text=" This phase Ib study aimed to determine the maximum tolerated dose (MTD) of dovitinib in combination with gemcitabine and capecitabine and to characterize the safety and pharmacokinetic profile in patients with advanced pancreatic and biliary tract cancers and solid malignancies"><entity charOffset="106-117" id="DDI-PubMed.30418178.s3.e0" text="gemcitabine" /><entity charOffset="122-134" id="DDI-PubMed.30418178.s3.e1" text="capecitabine" /><pair ddi="false" e1="DDI-PubMed.30418178.s3.e0" e2="DDI-PubMed.30418178.s3.e0" /><pair ddi="false" e1="DDI-PubMed.30418178.s3.e0" e2="DDI-PubMed.30418178.s3.e1" /></sentence><sentence text="" /><sentence text="Patients received gemcitabine 1000 mg/m² intravenously on days 1 and 8, capecitabine 1300 mg/m² oral daily from day 1 to 14, and dovitinib oral daily 5 days on and 2 days off, every 21-day cycle"><entity charOffset="18-29" id="DDI-PubMed.30418178.s5.e0" text="gemcitabine" /><entity charOffset="72-84" id="DDI-PubMed.30418178.s5.e1" text="capecitabine" /><entity charOffset="129-138" id="DDI-PubMed.30418178.s5.e2" text="dovitinib" /><pair ddi="false" e1="DDI-PubMed.30418178.s5.e0" e2="DDI-PubMed.30418178.s5.e0" /><pair ddi="false" e1="DDI-PubMed.30418178.s5.e0" e2="DDI-PubMed.30418178.s5.e1" /><pair ddi="false" e1="DDI-PubMed.30418178.s5.e0" e2="DDI-PubMed.30418178.s5.e2" /><pair ddi="false" e1="DDI-PubMed.30418178.s5.e1" e2="DDI-PubMed.30418178.s5.e1" /><pair ddi="false" e1="DDI-PubMed.30418178.s5.e1" e2="DDI-PubMed.30418178.s5.e2" /></sentence><sentence text=" The standard 3+3 dose escalation design was utilized and the study expanded to treat an additional 20 advanced pancreatic and biliary tract cancers patients at MTD" /><sentence text="" /><sentence text="A total of 29 patients were enrolled" /><sentence text=" One patient experienced dose-limiting grade 3 colitis" /><sentence text=" Two patients developed clinically significant neuropathy after the first cycle requiring dose reduction" /><sentence text=" The MTD was not reached and dovitinib 300 mg was declared the recommended dose for expansion" /><sentence text=" The most frequent grade 2 or worse adverse events were fatigue (45%), neutropenia (41%), thrombocytopenia (34%), anemia (24%), nausea (24%), and palmer-plantar erythrodysaesthesia syndrome (21%)" /><sentence text=" Partial responses were observed in 5 patients" /><sentence text=" Pharmacokinetic studies showed no drug-drug interaction between dovitinib, capecitabine and gemcitabine"><entity charOffset="76-88" id="DDI-PubMed.30418178.s14.e0" text="capecitabine" /><entity charOffset="93-104" id="DDI-PubMed.30418178.s14.e1" text="gemcitabine" /><pair ddi="false" e1="DDI-PubMed.30418178.s14.e0" e2="DDI-PubMed.30418178.s14.e0" /><pair ddi="false" e1="DDI-PubMed.30418178.s14.e0" e2="DDI-PubMed.30418178.s14.e1" /></sentence><sentence text=" Fibroblast growth factor 23 plasma level increased in 4 of 5 patients during the first cycle of treatment" /><sentence text="" /><sentence text="Dovitinib 300 mg daily is the recommended dose when combined with gemcitabine and capecitabine, achieving clinically relevant plasma concentrations"><entity charOffset="0-9" id="DDI-PubMed.30418178.s17.e0" text="Dovitinib" /><entity charOffset="66-77" id="DDI-PubMed.30418178.s17.e1" text="gemcitabine" /><entity charOffset="82-94" id="DDI-PubMed.30418178.s17.e2" text="capecitabine" /><pair ddi="false" e1="DDI-PubMed.30418178.s17.e0" e2="DDI-PubMed.30418178.s17.e0" /><pair ddi="false" e1="DDI-PubMed.30418178.s17.e0" e2="DDI-PubMed.30418178.s17.e1" /><pair ddi="false" e1="DDI-PubMed.30418178.s17.e0" e2="DDI-PubMed.30418178.s17.e2" /><pair ddi="false" e1="DDI-PubMed.30418178.s17.e1" e2="DDI-PubMed.30418178.s17.e1" /><pair ddi="false" e1="DDI-PubMed.30418178.s17.e1" e2="DDI-PubMed.30418178.s17.e2" /></sentence><sentence text=" The study combination demonstrated encouraging efficacy signals in advanced pancreatic cancer" /><sentence text="" /></document>